Propanc Biopharma Inc. Common Stock (PPCB)
Stock · NASDAQ · Health Care
$0.3327as of 10/16/2026
Price chart
Active signals
PPCB Signal Track Record
How signals performed across all stocks →What PPCB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | -32.9% | 18% | October 7, 2026 |
| Bollinger Band Breakdown | 22 | -13.5% | 32% | July 29, 2026 |
| Bollinger Band Breakout | 12 | -45.1% | 0% | August 27, 2026 |
| Any 20-session window (baseline) | -27.5% | 18% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a resea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2
- Website
- www.propanc.com/
Fundamentals
- 1-day range
- $0.325$0.4025
- Market cap
- $4.76M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-25.66
- Dividend yield
- —
- Beta
- 3.18
- Avg. volume
- 1.81M
- Dividend pay date
- November 19, 2020
Propanc Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PPCBPropanc Biopharma Inc. Common Stock$0.342▲ 0.15%Market cap $4.76MP/E —$0.365$47.5
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- ERNAErnexa Therapeutics Inc. Common Stock$2.09▼ 3.69%Market cap $5.09MP/E —$2.01$71.5
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PPCB Propanc Biopharma Inc. Common Stock | $4.76M | — | $0.342 | ▲ 0.15% | $0.365$47.5 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| ERNA Ernexa Therapeutics Inc. Common Stock | $5.09M | — | $2.09 | ▼ 3.69% | $2.01$71.5 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancerbenzinga · 10/16/2026
- Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ DaraxonrasibYahoo · 10/7/2026
- Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common StockBenzinga · 10/5/2026
- Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial ResultsYahoo · 9/29/2026
- Propanc Biopharma Q4 EPS $(0.10)Benzinga · 9/29/2026
- Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015Yahoo · 9/22/2026
- Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RASBenzinga · 9/22/2026
- Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.Yahoo · 9/16/2026
- Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015Benzinga · 9/16/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Propanc Biopharma releases corporate update and Q4 earnings
Propanc Biopharma issued a corporate update covering its year‑end June 30, 2025‑26 financial results. The company reported a fourth‑quarter earnings per share of negative $0.10. The update provides insight into recent performance as the stock trades near its recent support level.
Propanc Biopharma releases corporate update and Q4 earnings. Propanc Biopharma issued a corporate update covering its year‑end June 30, 2025‑26 financial results. The company reported a fourth‑quarter earnings per share of negative $0.10. The update provides insight into recent performance as the stock trades near its recent support level.